OptiBiotix Health PLC Intention to float SkinBiotherapeutics (0846A)
21 March 2017 - 11:00PM
UK Regulatory
TIDMOPTI
RNS Number : 0846A
OptiBiotix Health PLC
21 March 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Intention to float SkinBiotherapeutics
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces that its majority owned subsidiary,
SkinBioTherapeutics (formerly SkinBiotix), intends to seek
Admission to AIM with an associated institutional and private
client investment manager fundraising. A Schedule One announcement
in relation to the proposed Admission was issued by the London
Stock Exchange earlier today.
On 5 July 2016, OptiBiotix announced its strategy to form
separate divisions, each containing its own technology platform, IP
portfolio, and specialised teams, which could in due course become
separate legal entities with the potential for a separate public
listing. On 5 October 2016, Martin Hunt was appointed as Non
Executive Chairman of SkinBiotherapeutics. On 20 October 2016,
OptiBiotix announced that it had invested a further GBP400,000 into
SkinBiotherapeutics via a Convertible Loan Agreement to build the
team, IP, and research & development programmes to progress
towards an Initial Public Offering. OptiBiotix's convertible loan
will be converted into Ordinary Shares in SkinBioTherapeutics on
Admission.
OptiBiotix's strategy is based on its belief that the diversity
of IP and commercial relationships across its four divisions
reduces shareholder risk whilst offering multiple opportunities for
value enhancement.
The planned Admission of SkinBioTherapeutics brings in non
dilutive funding and creates the opportunity to drive the
development and commercialisation of its SkinBiotix(R) technology
platform to address large scale global markets in skin health
including Cosmetic Skin Care ($121bn); Health Care Acquired
Infections ($82bn); and Eczema ($3.8bn).
Stephen O'Hara, CEO of OptiBiotix, commented: "The rapid
development and growing awareness in the microbiome have been
matched by OptiBiotix's progress in a number of diverse areas of
key scientific and commercial interest. OptiBiotix's skin division
has built its own IP, team, and development programmes to a point
where the Board believe the scale of the opportunities offered by
its SkinBiotix's(R) technology in the biotherapeutic space may be
best realised by separate listing. As a majority shareholder in
SkinBioTherapeutics, OptiBiotix's Board believe this provides the
necessary resources to grow SkinBiotherapeutics and create the
potential for substantial future value enhancement."
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213
0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(TM), is based upon discoveries made by CEO Dr. Catherine
O'Neill and Professor Andrew McBain.
Following a breakthrough in microbiome research,
SkinBioTherapeutics' platform applies research discoveries made on
the activities of lysates derived from probiotic bacteria when
applied to the skin. The Company has shown that the SkinBiotix(TM)
platform can improve the barrier effect of skin models - from
moisture retention to anti-infection to repair.
SkinBioTherapeutics is targeting three specific markets;
cosmetics, infection control and eczema. In each of these areas the
Company intends to exemplify its technology in human studies. The
most advanced programme is focused on creating an ingredient for
the cosmetics industry to treat sensitive skin. The business
strategy is to outlicense its programmes at proof of concept.
SkinBioTherapeutics received seed funding from the Tech Transfer
office of the University of Manchester for the discovery of
SkinBiotix(TM). The platform was subsequently spun out of the
University of Manchester in March 2016 and was funded by OptiBiotix
(AIM: OPTI).
The Company is based in Manchester, UK. For more information,
visit www.skinbiotherapeutics.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCFFLFLDXFEBBE
(END) Dow Jones Newswires
March 21, 2017 08:00 ET (12:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024